Safe and short time treatment of superficial and unresectable deep tumors
- Registration Number
- IRCT20190904044697N5
- Lead Sponsor
- Iran Nano Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Cancer patients who have different types of cancer with solid tumors.
Patients who the biopsy results of their tumors approved that the tumors are malignant
Patients with any superficial and unresectable deep tumors
Patients with highest levels of invasion are more appropriate for receiving treatment (i.e. triple negative breast cancer and gastrointestinal invasive cancers)
Pathological or radiological evidence of progression of the disease despite common treatments
Patients with end-stage cancer who oncologists confirm that they did not profit from an alternative treatment, can include the study as a palliative therapy
Patients with different types of benign and malignant tumors
Patients who do not have a definable and discriminating mass to evaluate response to treatment.
pregnancy
Patients who do not have appropriate general condition and need intensive care.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in the size and extent of tumor necrosis. Timepoint: one week. Method of measurement: Imaging modalities (Conventional ultrasound and especially Doppler ultrasound, MRI and CT scan), Immunohistochemistry, pathological and microscopical markers and cellular staining.;Clinical and quality of life changes. Timepoint: Every day. Method of measurement: Blood Test, Investigating of Clinical Manifestation.
- Secondary Outcome Measures
Name Time Method Quality Of Life. Timepoint: 90 days. Method of measurement: Questionnaire about quality of life indicators based on EORTC QLQ-C30.